DeepMed Research

Chong Kun Dang Pharmaceutical Corp.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1941-01-01

Employees: 2.3K

Market Cap: -

Website: http://www.ckdpharm.com

Clinical Trials

Drug-drug Interaction Study(CKD-501, Amlodipine)

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-501
Drug: CKD-501 amlodipine
Drug: amlodiopine

First Posted Date: 2011-04-25

Last Posted Date: 2011-08-15

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 25

Registration Number: NCT01341392

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers

Phase 1

Completed

Conditions: Chronic Stable Angina

Interventions: Drug: Dilatrend 64mg capsule

First Posted Date: 2011-04-22

Last Posted Date: 2011-12-22

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01340248

Locations: 🇰🇷
Kyungpook national university, Daegu, Seoul, Korea, Republic of

CKD-828 (40/5mg) Pharmacokinetic Study

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: CKD-828
Drug: Combination Therapy

First Posted Date: 2011-04-22

Last Posted Date: 2011-04-28

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 68

Registration Number: NCT01340131

Locations: 🇰🇷
Inje University Pusan Paik Hospital, Pusan, Korea, Republic of

Drug-drug Interaction Study (CKD-501, Ketoconazole)

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-501, Ketoconazole

First Posted Date: 2011-04-07

Last Posted Date: 2011-06-29

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01330563

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

Study to Evaluate the Pharmacokinetic Characteristics of Luckyvec 400mg Tablet, in Healthy Subjects

Phase 1

Completed

Conditions: Chronic Myeloid Leukemia
Gastrointestinal Stromal Tumors

Interventions: Drug: Glivec 100mg film coated tablet
Drug: Luckyvec 400mg film coated tablet

First Posted Date: 2011-01-06

Last Posted Date: 2012-10-31

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 30

Registration Number: NCT01270984

Locations: 🇰🇷
The Korea University Anam Hospital, Seoul, Korea, Republic of

CKD-828(80/2.5mg) Pharmacokinetic Study

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: CKD-828(FDC)
Drug: Combination Therapy

First Posted Date: 2010-11-23

Last Posted Date: 2011-01-19

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 65

Registration Number: NCT01246193

Locations: 🇰🇷
Inje Unuversity Pusan Paik Hospital, Pusan, Korea, Republic of

The Pharmacokinetic Interaction Between CKD-501 and Sulfonylurea

Phase 1

Completed

Conditions: Healthy Male Volunteer

Interventions: Drug: CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet
Drug: CKD-501 placebo tablet, Glimepiride 4 mg tablet

First Posted Date: 2010-05-28

Last Posted Date: 2010-12-10

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01133431

Locations: 🇰🇷
The Korea University Anam Hospital, Seoul, Korea, Republic of

CKD-828 Primary Hypertension Trial(Dose-selection)

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: Placebo
Drug: S-Amlodipine, Telmisartan
Drug: S-Amlodipine
Drug: Telmisartan

First Posted Date: 2010-05-21

Last Posted Date: 2011-04-26

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 430

Registration Number: NCT01128322

Locations: 🇰🇷
Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of
🇰🇷
DonGuk University International Hospital, Goyang, Korea, Republic of

and more 23 locations

Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to Metformin

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: CKD-501 0.5mg
Drug: Pioglitazone 15mg

First Posted Date: 2010-04-19

Last Posted Date: 2013-02-15

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 253

Registration Number: NCT01106131

Locations: 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of

The Effect of Food on the Pharmacokinetic Characteristics of CKD-501

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CKD-501 1mg

First Posted Date: 2010-02-19

Last Posted Date: 2010-12-10

Lead Sponsor: Chong Kun Dang Pharmaceutical

Target Recruit Count: 24

Registration Number: NCT01071720

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy